WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
fiercebiotech | August 21, 2017
Blade Therapeutics is looking to sharpen its focus after hiring Bristol-Myers Squibb’s former fibrosis research lead as its new EVP of research. The biotech, which is working on antifibrotic (scarring) therapies, has appointed Maria E. Fuentes, Ph.D., to lead its antifibrotic programs in preclinical testing. Blade’s flagship program, focused on a small molecule cysteine protease inhibitor, is expected to enter IND-enabling studies by year-end 2017. Fuentes comes to the small, private...
Biospace | May 13, 2019
May has been a fairly slow month for approvals by the U.S. Food and Drug Administration (FDA). There are currently only two scheduled for the rest of the month, with a third that has been withdrawn. Let’s take a look. Regeneron’s Eylea for Diabetic Retinopathy Regeneron Pharmaceuticals has a target action date of May 13 for its supplemental Biologics License Application (sBLA) of Eylea (aflibercept) injection for diabetic retinopathy (DR). DR is the leading cause of vision loss in di...
Drug Target Review | January 15, 2020
Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...
Labiotech | January 15, 2020
The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...
CELL AND GENE THERAPY
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE